MgSO₄ acts primarily through the magnesium ion (Mg²⁺), a physiological, voltage-dependent open-channel blocker of NMDA receptors that reduces calcium influx during excitatory synaptic transmission and raises the seizure threshold by dampening glutamatergic drive (Magee et al., 2022b; Wilcox et al., 2022). At resting membrane potentials, Mg²⁺ occupies the NMDA receptor pore and is expelled during depolarization; therapeutically increasing extracellular Mg²⁺ strengthens this block and helps stabilize cortical networks (Magee et al., 2022b; Wilcox et al., 2022). Beyond NMDA receptors, Mg²⁺ modulates voltage-gated calcium channels—particularly L-type (CaV1.x) channels on vascular smooth muscle and presynaptic N-/P/Q-type (CaV2.x) channels—thereby reducing presynaptic Ca²⁺ entry and neurotransmitter release while promoting vasorelaxation (Catterall, 2023; Ch et al., 2022).

At the neuromuscular junction, Mg²⁺ inhibits presynaptic acetylcholine release and slightly decreases postsynaptic sensitivity, which clinically potentiates nondepolarizing neuromuscular blocking agents. Meticulous quantitative neuromuscular monitoring and appropriate reversal are therefore recommended when perioperative or ICU MgSO₄ exposure coexists with nondepolarizing neuromuscular blocking agents (Thilen et al., 2023; Dahake et al., 2024).

Clinically, the ionized fraction of magnesium (iMg²⁺) is the active moiety, whereas total serum magnesium correlates imperfectly with iMg²⁺ in critical illness. Renal handling—filtration and reabsorption primarily in the thick ascending limb—and acid–base status influence iMg²⁺ availability (Adomako and Yu, 2024). Limited, historical human data show only modest increases in cerebrospinal fluid magnesium after IV MgSO₄; because cerebrospinal fluid magnesium is an imperfect surrogate for synaptic/interstitial exposure, these observations are best interpreted as consistent with central nervous system effects arising from enhanced synaptic excitability control (e.g., NMDA/Ca²⁺-linked mechanisms) together with cerebrovascular/endothelial actions, rather than from large bulk blood–brain barrier transfer (Thurnau et al., 1987).

Beyond these proximal electrophysiologic effects, MgSO₄ has been shown to modulate intracellular inflammatory signaling and transcriptional outputs relevant to endothelial activation. In human umbilical vein endothelial cells, MgSO₄ reduced nuclear factor kappa B (NF-κB) nuclear translocation and preserved inhibitor of κB alpha, with downstream suppression of interleukin-8 release and intercellular adhesion molecule 1 expression after lipopolysaccharide stimulation (Rochelson et al., 2007). In innate immune and neuroinflammation models, clinically relevant MgSO₄ exposure reduced pro-inflammatory cytokine production (including tumor necrosis factor alpha and interleukin-6) and was associated with increased basal inhibitor of κB alpha and reduced NF-κB activation; in lipopolysaccharide-activated primary microglia, MgSO₄ inhibited NF-κB translocation and decreased interleukin-1 beta (IL-1β) and tumor necrosis factor alpha release (with concurrent reductions in nitric oxide/prostaglandin E2) (Sugimoto et al., 2012; Gao et al., 2013). In pregnancy-specific models, MgSO₄ suppressed placental NF-κB–linked inflammation in a lipopolysaccharide-induced preeclampsia-like rat model (including reduced placental IL-1β/interleukin-12 with improved placental function and angiogenesis signals) and attenuated excessive placental cytokine secretion in ex vivo perfusion studies of preeclamptic placentas (e.g., reduced maternal-side IL-1β secretion and altered interleukin-1 receptor antagonist dynamics) (Wu et al., 2023; Amash et al., 2012).

At the organelle level, MgSO₄ has been linked to mitochondrial protection and apoptosis-pathway modulation: in hypoxia-stress neuronal models, MgSO₄ preserved mitochondrial membrane potential, reduced cytochrome-c release, increased anti-apoptotic B-cell lymphoma 2 family proteins, and engaged mitogen-activated protein kinase signaling (extracellular signal–regulated kinase 1/2 activation with attenuation of p38 mitogen-activated protein kinase/c-Jun N-terminal kinase activity), consistent with improved cellular resilience (Huang et al., 2015; Huang et al., 2010). Consistent with bioenergetic relevance, MgSO₄ reduced brain-mitochondria oxidative damage after experimental hypoxia and improved mitochondrial respiratory function indices in brain-injury models (Mohammadi et al., 2020; Xu et al., 2002). Given oxidative stress as a key driver in placental pathology, we additionally note nuclear factor erythroid 2–related factor 2-centered antioxidant transcription as a plausible integrating axis; in a pregnancy rat model, MgSO₄ increased placental nuclear factor erythroid 2–related factor 2 (and antioxidant proteins such as peroxiredoxin 6) while reducing inflammatory cytokines (e.g., IL-1β, tumor necrosis factor alpha, interferon-gamma), supporting biologic plausibility that MgSO₄ can couple anti-inflammatory and antioxidant programs, although direct confirmation in preeclampsia tissues remains limited (Han et al., 2018). Finally, angiogenic signaling can also be MgSO₄-responsive: placental perfusion data suggest MgSO₄ can alter vascular endothelial growth factor expression in a compartment- and phenotype-dependent manner, and placental ischemia models demonstrate reductions in cerebrospinal fluid vascular endothelial growth factor alongside cytokine/chemokine attenuation with MgSO₄ (Weintraub et al., 2013; Zhang and Warrington, 2016). To date, pregnancy-tissue–specific data directly interrogating MgSO₄ effects on canonical transforming growth factor beta/SMAD signaling are sparse; targeted mechanistic studies are therefore warranted. For an overview of preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum, see Bisson et al. (2023).

Pregnancy alters Mg²⁺ pharmacokinetics through hemodilution, increased glomerular filtration rate (GFR), and changes in gastrointestinal absorption and volume of distribution across maternal–fetal compartments. Placental transfer occurs, with fetal exposure directly relevant to neuroprotection (Magee et al., 2022b). Population-based and clinical data emphasize that reduced renal clearance elevates toxicity risk, whereas augmented clearance in late gestation may lower total serum magnesium and iMg²⁺ for a given dose. Accordingly, renal function and clinical context should inform monitoring targets (e.g., reflexes, respiration, urine output) and, where available, selective use of iMg²⁺ measurement (Magee et al., 2022b; Adomako and Yu, 2024).

One “single dominant pathway” view holds that NMDA antagonism sufficiently explains MgSO₄’s antiseizure efficacy by curbing glutamate-mediated excitotoxicity and neuronal synchrony (Magee et al., 2022b; Wilcox et al., 2022). In contrast, a “multipathway synergy” model proposes that combined NMDA blockade, voltage-gated calcium channel modulation, endothelial stabilization, and cerebrovascular effects jointly raise seizure threshold, smooth perfusion, and reduce edema—more consistent with the multisystem pathobiology of preeclampsia and eclampsia (National Institute for Health and Car e Excellence NICE, 2015; Magee et al., 2022b). Current consensus favors a multimechanistic framework, acknowledging that the relative contribution of each pathway likely varies by disease stage, GA, and concomitant therapies. Ongoing work integrating electrophysiology, imaging, and vascular biomarkers may refine these relative weights (National Institute for Health and Car e Excellence NICE, 2015; Magee et al., 2022b; Wilcox et al., 2022).

Figure 1 schematically integrates MgSO₄ actions on the central nervous system, vasculature, neuromuscular junction, and the preterm brain with bedside monitoring implications.

MgSO₄ is distributed primarily within the extracellular space, with renal excretion as the dominant elimination pathway; impaired glomerular filtration markedly reduces clearance and prolongs exposure (Adomako and Yu, 2024). Contemporary population PK (popPK) work in women with preeclampsia modeled MgSO₄ with an apparent clearance of ∼2.98 L/h and a volume of distribution of ∼25.1 L, consistent with mainly extracellular distribution and the clinically observed accumulation when renal function declines (Deng et al., 2024). After IV loading, anticonvulsant effects are rapid; intramuscular (IM) absorption is slower and more variable, with clinical references noting near-immediate onset for IV dosing versus delayed and less predictable uptake after IM administration (Hicks and Tyagi, 2023). In an IM-focused PK study in preeclampsia, fewer than two-thirds of participants achieved serum Mg²⁺ ≥2.0 mmol/L by ∼12 h, underscoring the variability of IM regimens (Brookfield et al., 2021).

Pregnancy-specific kinetics interact with these parameters. Expanded plasma volume and increased GFR in normal gestation alter distribution and renal handling, while preeclampsia and its therapies introduce additional heterogeneity (Dimitriadis et al., 2023). Clinically, steady exposure under continuous infusion reflects the balance between distribution and renal elimination; diminished GFR (acute kidney injury or chronic impairment) shifts this balance toward accumulation and elevated toxicity risk (Adomako and Yu, 2024).

Gestation-associated increases in plasma volume and GFR affect both volume of distribution and clearance; these physiologic shifts, together with disease severity, help explain the interindividual variability seen with standardized dosing in preeclampsia (Dimitriadis et al., 2023). In a 2024 popPK analysis from a Chinese preeclampsia cohort, creatinine clearance (CrCl), body mass index (BMI), and concurrent furosemide significantly influenced drug disposition: higher CrCl and BMI were associated with lower concentrations at a given dose, and diuretic use modified maintenance requirements (Deng et al., 2024). Earlier modeling similarly identified body weight and renal function as major covariates, with higher body weight increasing volume of distribution and effectively reducing the elimination rate under fixed dosing (da Costa et al., 2020). Consistent with these findings, a RCTs in women with obesity (BMI ≥35 kg/m²) showed that an “alternate” regimen with a higher maintenance infusion improved attainment of therapeutic levels compared with a standard regimen, supporting weight-informed dose selection in high-BMI populations (Brookfield et al., 2020).

Renal impairment magnifies risk. Because magnesium is cleared renally, reductions in GFR lead to disproportionate increases in serum levels under typical prophylactic infusions; hypermagnesemia with loss of deep-tendon reflexes (DTRs), respiratory depression, and conduction abnormalities can ensue (Adomako and Yu, 2024). Severe iatrogenic hypermagnesemia—most often occurring in the context of renal dysfunction—should prompt immediate cessation of MgSO₄, IV calcium to antagonize neuromuscular and cardiac effects, aggressive hydration as appropriate, and hemodialysis for refractory or life-threatening toxicity. Contemporary case reports document rapid clinical recovery with dialysis (Si et al., 2024; Miri et al., 2025).

Figure 2 illustrates the concentration–time profile, therapeutic window (2.0–3.5 mmol/L), and toxicity thresholds, including contextual shifts in exposure.

Recent popPK studies in preeclampsia generally favor parsimonious structural models—often one-compartment with first-order elimination—capturing substantial between-subject variability via covariates such as weight/BMI, CrCl/serum creatinine, and diuretic exposure (Deng et al., 2024; da Costa et al., 2020). In a recent Chinese population PK model for preeclampsia, Monte Carlo simulations suggested that to maintain 2.0–3.5 mmol/L (≈4.9–8.5 mg/dL), a 5 g IV loading dose followed by up to ∼10 g/day maintenance was often required in patients not receiving furosemide, whereas lower maintenance doses (∼2.5 g/day) sufficed when furosemide reduced levels through diuresis; these proposals were explicitly tied to simulated target-attainment probabilities (Deng et al., 2024). The obesity-focused RCT complements the model outputs by demonstrating improved pharmacodynamic target attainment with higher maintenance rates in high-BMI patients on standard obstetric regimens (Brookfield et al., 2020). Collectively, these data support model-informed dose adjustments in patients with extremes of body weight and altered renal function, while recognizing that bedside toxicity monitoring remains the final safety backstop.

Across obstetric trials, PK studies, and guideline summaries, total serum magnesium concentrations of approximately 2.0–3.5 mmol/L (≈4.9–8.5 mg/dL; 1 mmol/L ≈ 2.43 mg/dL) are commonly cited as the therapeutic range for seizure prophylaxis and treatment in eclampsia and severe preeclampsia (Hicks and Tyagi, 2023; Rosanoff et al., 2022). Within this window, most patients achieve reliable anticonvulsant and neuroprotective effects with an acceptable safety profile, a conclusion echoed across obstetric guidance and recent reviews (De Oliveira et al., 2024; National Institute for Health and Care Excellence NICE, 2019).

As total magnesium rises above the therapeutic range, toxicity tends to follow a predictable clinical sequence. Loss of DTRs is typically reported at concentrations around 4.0–5.0 mmol/L (≈9.7–12.2 mg/dL), followed by progressive respiratory depression at roughly 5.0–7.5 mmol/L (≈12–18 mg/dL), with atrioventricular conduction block and cardiac arrest described at levels exceeding 12.5–15.0 mmol/L (≈30–36 mg/dL) (Hicks and Tyagi, 2023; Rosanoff et al., 2022). These numeric thresholds vary between reports because total serum magnesium includes protein-bound and complexed fractions, whereas only about one-half to two-thirds circulates as ionized, physiologically active Mg²⁺; shifts in pH and albumin can therefore alter the relationship between total and effect-site exposure (Adomako and Yu, 2024). In routine practice, ionized magnesium assays remain limited, so total magnesium is used as a surrogate marker and interpreted alongside bedside signs (respiratory rate, DTRs, urine output) rather than as a stand-alone determinant of safety or toxicity.

Most obstetric guidelines and good-practice statements place bedside clinical examination at the center of MgSO₄ safety monitoring. Serial assessment of DTRs, respiratory rate, and urine output is recommended as the primary safeguard against toxicity, with serum magnesium levels obtained selectively rather than on a fixed schedule (National Institute for Health and Care Excellence (NICE), 2019; Shennan et al., 2021; The ObG Project, 2023). This “clinical-first” approach aligns with the exposure–toxicity sequence summarized in Section 4.4 and reflects the reality that neuromuscular and respiratory changes often precede the availability of laboratory results. In hemodynamically stable patients with preserved renal function receiving standard obstetric regimens, several consensus summaries explicitly state that routine levels are not required (National Institute for Health and Care Excellence (NICE), 2019; Shennan et al., 2021; The ObG Project, 2023).

Serum magnesium measurements play a complementary, targeted role in higher-risk or more complex situations. Because PK variability in preeclampsia, obesity, diuretic use, and renal dysfunction can shift exposure at a given dose (Deng et al., 2024; Hicks and Tyagi, 2023; De Oliveira et al., 2024), levels are useful when: (i) renal function is impaired or deteriorating; (ii) BMI is extreme or dosing deviates from standard protocols; (iii) clinical signs are equivocal or DTRs are unreliable; or (iv) co-therapies plausibly alter magnesium handling (Deng et al., 2024; Adomako and Yu, 2024; Hicks and Tyagi, 2023; National Institute for Health and Care Excellence (NICE), 2019; Shennan et al., 2021; The ObG Project, 2023). In these scenarios, total serum magnesium is interpreted alongside bedside findings to confirm extremes of exposure and guide dose adjustment or interruption, rather than replace clinical monitoring. A more detailed discussion of the “clinical signs versus routine levels” debate is provided in Section 8.1, and practice-ready action steps are summarized in Box 1 (Practice checklist).

Across operating rooms (ORs), post-anesthesia care units (PACUs), and ICUs, IV MgSO₄ has reproducible anesthetic- and analgesic-sparing effects attributable to NMDA receptor antagonism and calcium-channel antagonism. A contemporary meta-analysis of spine surgery randomized trials shows lower postoperative opioid consumption at 24 h, reduced intraoperative remifentanil requirements, and a clinically meaningful decrease in postoperative nausea and vomiting, with a trade-off of slightly prolonged orientation and recovery times—placing MgSO₄ as a reasonable adjunct when early opioid minimization and postoperative nausea and vomiting reduction are priorities (Yue et al., 2022). Evidence outside spine surgery is directionally consistent: in elderly patients undergoing Endoscopic Retrograde Cholangiopancreatography with propofol-based sedation, a single 40 mg/kg MgSO₄ bolus reduced propofol use by ≈ 21% and lowered respiratory depression and involuntary-movement events without prolonging recovery, supporting a dose-sparing role during titrated hypnotic sedation (Chen et al., 2023). Randomized perioperative data also suggest reduced emergence agitation and lower intraoperative remifentanil requirements when MgSO₄ is added to general anesthesia, aligning with its central antinociceptive profile (Su et al., 2023).

Drug–drug interactions are central to safe co-administration. With propofol, MgSO₄ typically lowers the hypnotic requirement; clinicians should anticipate lower doses to achieve comparable sedation targets and monitor for delayed awakening when high total hypnotic/adjunct loads accrue (Yue et al., 2022; Chen et al., 2023). When combined with dexmedetomidine, hemodynamic depressant effects may be additive, because dexmedetomidine independently increases intraoperative hypotension and bradycardia—particularly when a loading dose is used—warranting cautious titration and readiness to treat bradycardia and vasodilatory hypotension (Wang et al., 2024). Co-administration with benzodiazepines and opioids can further reduce opioid need via NMDA antagonism, but practitioners should watch for enhanced central nervous system depression and slower emergence in susceptible patients, especially older adults and those receiving multiple sedatives (Yue et al., 2022; Chen et al., 2023).

Potentiation of nondepolarizing neuromuscular blockers (NMBs)—notably rocuronium—remains a practical concern because Mg²⁺ decreases presynaptic acetylcholine release and postsynaptic excitability. Accordingly, the 2023 American Society of Anesthesiologists guideline recommends quantitative neuromuscular monitoring and pharmacologic reversal guided by objective train-of-four metrics to avoid residual paralysis in any setting where NMBs are used and potentiation is possible (Thilen et al., 2023).

In obstetric anesthesia, benefit–risk evaluation must also consider uterine tone. A 2021 meta-analysis found no significant increase in uterine atony or postpartum hemorrhage among women receiving MgSO₄ versus those not receiving MgSO₄, tempering concerns that adjunct use inevitably worsens uterine contractility; nonetheless, vigilance for hypotension and careful titration around delivery remain good practice (Pergialiotis et al., 2021).

Figure 4 consolidates practical guardrails for adjunct MgSO₄ use in the OR/PACU/ICU—goals, titration with bedside safety thresholds, dexmedetomidine interaction, quantitative NMB monitoring and reversal, and obstetric hemorrhage safeguards.

For perioperative/ICU adjunct use—titration, interactions, NMB monitoring, and obstetric precautions—see Box 1 (Practice checklist).

Maternal adverse effects are usually mild and dose related—flushing, warmth, nausea, vomiting, lethargy, dizziness—and rarely require discontinuation when infusions are titrated and clinical signs are monitored (Shepherd et al., 2024; Brookfield and Mbata, 2023). More serious events include hypotension, respiratory depression or arrest, atrioventricular conduction block, and cardiac arrest, typically in the setting of excessive serum magnesium (e.g., reduced glomerular filtration) or concurrent sedatives/neuromuscular blockers (Adomako and Yu, 2024; Magley et al., 2025; Merck & Co. and Inc, 2025). In randomized trials and systematic reviews of antenatal neuroprotection, serious maternal adverse events were uncommon and generally manageable with protocolized monitoring (Shepherd et al., 2024).

Neonatal effects after in utero exposure near delivery may include transient hypotonia, lower Apgar scores, or short-term NICU admission signals in some cohorts; however, these findings must be interpreted against consistent reductions in CP and the composite of death or CP among very preterm infants exposed to antenatal MgSO₄, without a clear adverse mortality signal (Shepherd et al., 2024). When high cumulative maternal dosing is given very close to delivery, nursery observation for tone and respiration is prudent (Shepherd et al., 2024; Brookfield and Mbata, 2023).

As detailed in Section 4.4, magnesium toxicity follows a concentration-dependent clinical sequence from loss of DTRs to progressive respiratory depression and, at extreme exposures, atrioventricular block and cardiac arrest, as summarized in pharmacology references and case series (Adomako and Yu, 2024; Merck & Co. and Inc, 2025). In practice, any significant neuromuscular or respiratory compromise in a patient receiving MgSO₄ should be treated as toxicity regardless of the measured level, with clinical signs guiding urgency and escalation.

Management begins with immediate discontinuation of MgSO₄ and prompt administration of IV calcium, typically 10 mL of 10% calcium gluconate (≈1 g) given slowly IV, to counteract neuromuscular and cardiac effects (Adomako and Yu, 2024; Magley et al., 2025; Merck & Co. and Inc, 2025). Supportive care includes airway protection and assisted ventilation as needed, isotonic fluids and loop diuretics when appropriate, and continuous cardiac and respiratory monitoring (Adomako and Yu, 2024; Magley et al., 2025; Merck & Co. and Inc, 2025). In severe or refractory hypermagnesemia—particularly in the setting of renal failure—hemodialysis or continuous renal replacement therapy provides enhanced elimination and should be considered early when clinical deterioration persists despite initial measures (Adomako and Yu, 2024; Magley et al., 2025).

Antenatal MgSO₄ for neuroprotection reduces CP and the composite of death/CP among early preterm births without a clear increase in neonatal mortality, and with low rates of serious maternal complications under protocolized care (Shepherd et al., 2024). Neonatal hypotonia or respiratory depression may occur after high maternal doses given close to delivery but is generally transient and manageable with supportive care (Shepherd et al., 2024). During breastfeeding, transfer into milk is minimal; the estimated relative infant dose is very low, and clinically important effects in breastfed term infants are unlikely, although monitoring is reasonable if the maternal infusion is ongoing immediately postpartum [Drugs and Lactation Database (LactMed®), 2006]. Drugs and Lactation Database and clinical reviews consider MgSO₄ compatible with breastfeeding [Brookfield and Mbata, 2023; Drugs and Lactation Database (LactMed®), 2006)].

Building on the exposure–toxicity relationships in Section 4.4 and the monitoring debate discussed in Section 8.1, current guidance supports a clinical-first, level-supported strategy for patients receiving MgSO₄. All patients should undergo baseline assessment of mental status, respiratory rate, DTRs, and urine output, followed by serial respiratory rate/deep tendon reflexes/urine output.

(RR/DTR/UO) checks at the bedside to prevent unrecognized accumulation and respiratory compromise (World Health Organization, 2025; Magee et al., 2022a; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). In hemodynamically stable patients with preserved renal function on standard obstetric regimens, many consensus statements indicate that routine serum magnesium levels are not required when examinations are reliable (World Health Organization, 2025; Magee et al., 2022a; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023).

Serum magnesium measurements are reserved for situations in which exposure is likely to be shifted or clinical signs are less trustworthy. Guidelines recommend selective levels in the presence of renal impairment or deterioration, prolonged infusions, extremes of body size or atypical dosing, and equivocal or confounded examinations (e.g., absent or unreliable reflexes) (World Health Organization, 2025; Magee et al., 2022a; Brookfield and Mbata, 2023; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). Where ionized magnesium (iMg²⁺) assays are unavailable, total serum magnesium remains the practical laboratory metric and is interpreted alongside bedside findings rather than in isolation (Adomako and Yu, 2024).

In anesthetic and critical-care settings, concurrent sedatives and NMBs increase the risk of apnea and residual paralysis. Professional guidance therefore recommends quantitative neuromuscular monitoring and agent-specific reversal to mitigate MgSO₄-related potentiation of NMBs, with the same principles of clinical-first monitoring and targeted levels applied in this higher-risk context (Thilen et al., 2023; Rodney et al., 2024).

As discussed in Section 8.1, dosing and monitoring in renal impairment and extreme BMI remain areas of active debate. From a practical standpoint, several principles are clear. Because magnesium is predominantly renally cleared, reduced glomerular filtration rate (acute kidney injury or chronic kidney disease) increases exposure at any given infusion rate and raises the risk of DTR loss, respiratory depression, and conduction defects (Adomako and Yu, 2024; Magley et al., 2025). In such patients, guidelines and reviews advise lower maintenance doses, cautious titration, and a lower threshold for checking levels or interrupting therapy when clinical signs become unreliable (World Health Organization, 2025; Magee et al., 2022a; Brookfield and Mbata, 2023; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). The goal is to keep exposure within the therapeutic range outlined in Section 4.4 while avoiding abrupt toxicity.

By contrast, obesity increases the apparent volume of distribution and can blunt concentrations achieved by fixed infusions. PopPK analyses in preeclampsia identify BMI/weight and creatinine clearance as key covariates influencing exposure, and simulations suggest that some individuals may require higher maintenance rates to reach the desired therapeutic range, whereas diuretics and reduced renal function lower requirements (Deng et al., 2024). Clinicians must balance underexposure (breakthrough seizures) against overexposure (toxicity), recognizing that model-informed dosing can complement but not replace bedside monitoring and serial clinical assessment (Magee et al., 2022a). Reviews also highlight that, in carefully selected patients, postpartum magnesium duration may be shortened (e.g., 12 h vs. 24 h) without increasing eclampsia, thereby reducing cumulative exposure, although practice varies and should align with local protocols and individual risk (Quist-Nelson et al., 2024).

In day-to-day care, a pragmatic approach is to maintain standard loading doses, apply modest maintenance adjustments in women with impaired or changing renal function or extreme BMI, and reserve serum magnesium levels for situations in which renal function is compromised, dosing deviates from standard regimens (such as high-BMI adjustments), or the clinical examination is unreliable (World Health Organization, 2025; Deng et al., 2024; Magee et al., 2022a; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). Section 8.1 expands on the underlying controversy around routine levels versus targeted monitoring, and Box 1 (Practice checklist) consolidates practical action steps and monitoring thresholds for these higher-risk groups.

Standardized electronic order sets that pair a MgSO₄ loading dose with maintenance, embed contraindications, and auto-populate nursing checks (respiratory rate, deep-tendon reflexes, urine output) are a cornerstone of reliable care in hypertensive emergencies of pregnancy. National bundles recommend enterprise-wide build and default escalation steps to reduce omissions and delays (Birth, 2022; Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025). Best Practice Advisories (BPAs) that fire on sustained severe BP and link directly to the order set can improve timeliness, but effects are heterogeneous and susceptible to alert fatigue unless trigger logic is tight and roles are clearly defined (Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025; Spencer et al., 2021). In a pre–post evaluation, an automated alert increased the proportion treated within 1 h yet had neutral effects on some downstream elements, underscoring that alerts must be embedded within end-to-end workflows (order sets, handoffs, escalation) rather than deployed in isolation (Spencer et al., 2021). High-performing sites also standardize default timing for laboratory surveillance in renal impairment (selective magnesium levels), document neuromuscular-monitoring plans when nondepolarizing blockers are used, and use auto-generated reassessment tasks at 15–30 min to close loops (Birth, 2022; Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025).

Digitized maternal early-warning systems Modified Early Warning Score/Modified Early Obstetric Warning System (MEWS/MEOWS) integrate vital signs and symptoms to trigger team responses and open the severe-hypertension pathway; a recent national development/validation provides a template for electronic health record (EHR) implementation with actionable thresholds that can automatically surface MgSO₄ and antihypertensive orders (Gerry et al., 2024). After discharge, remote postpartum BP programs with algorithm-driven triage detect more hypertension and reduce readmissions, providing a structured pathway for timely antihypertensives and reconsideration of MgSO₄ when neurologic symptoms or severe features emerge (Mujic et al., 2024; Hauspurg et al., 2024). The 2025 American Heart Association Scientific Statement endorses structured remote monitoring and explicit escalation timelines in the postpartum period (Countouris et al., 2025).

The AIM Severe Hypertension in Pregnancy safety bundle organizes work into Readiness, Recognition/Prevention, Response, and Reporting/Learning, explicitly pairing MgSO₄ for seizure prophylaxis/treatment with rapid-acting antihypertensives, team roles, and data capture (Birth, 2022). The Institute for Healthcare Improvement/AIM Change Package operationalizes this framework with simulation scripts, standardized handoffs, and bedside nursing checklists that document reflexes, respirations, urine output, and infusion integrity at defined intervals (Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025). Central to these programs is the process metric “treat severe BP within 30–60 min”—with repeat BP at 15 minutes—tracked via simple run charts or statistical process control to drive weekly feedback and course correction (California Maternal Quality Care Collaborative CMQCC, 2022; Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025; Combs et al., 2022). California Maternal Quality Care Collaborative materials translate the metric into practical steps (who repeats the BP, who orders, who administers the dose) to compress latency in real care environments (California Maternal Quality Care Collaborative CMQCC, 2022).

State perinatal quality collaboratives and health systems implementing AIM report increases in the proportion of patients treated within 60 min and concurrent improvements in reliability of MgSO₄ administration for indicated patients. Several collaboratives also report declines in HDP-related severe maternal morbidity (SMM), though effects vary with baseline performance, staffing, and bundle uptake (Birth, 2022). Neutral or mixed findings are common when sites deploy EHR alerts without parallel work on order-set adoption, role clarity, and bedside checklists, emphasizing the importance of a whole-system approach (Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025; Spencer et al., 2021). Across programs, equity stratifiers (race/ethnicity, language, rurality) are applied to every key performance indicators (KPIs) so that closing gaps is an explicit objective rather than an incidental outcome—an approach increasingly embedded in AIM and California Maternal Quality Care Collaborative dashboards (California Maternal Quality Care Collaborative (CMQCC), 2022; Birth, 2022; Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025).

Where pumps and laboratories are limited, feasible MgSO₄ regimens (e.g., protocolized IV or IM maintenance), simplified observation sheets, and paper-to-digital escalation pathways enable safe implementation at district hospitals (California Maternal Quality Care Collaborative CMQCC, 2022). The WHO Fact Sheet identifies MgSO₄ underuse as a remediable systems failure and urges national adoption of standardized protocols, supply-chain assurance, and routine audit-and-feedback (California Maternal Quality Care Collaborative CMQCC, 2022). WHO’s QCN provides an implementation architecture—from national coaching to facility-level micro-audits—with tools that can be adapted for MgSO₄ order sets, bedside checklists, and data flows as sites digitize over time (World Health Organization). These resources offer a pragmatic “on-ramp” for facilities beginning with paper algorithms and gradually advancing to EHR-integrated workflows.

Inputs → Activities → Outputs → Outcomes: leadership + stocked kits + EHR builds + training → order sets + BPAs + early-warning systems + simulations + remote BP programs + dashboards → faster initiation, complete monitoring, reliable handoffs → more cases treated in ≤60 min, higher indicated MgSO₄ use, fewer eclampsia/SMM events, and narrowed equity gaps (Countouris et al., 2025; California Maternal Quality Care Collaborative (CMQCC), 2022; Birth, 2022; Institute for Healthcare Improvement. AIM Patient Safety Bundles, 2025; Gerry et al., 2024; World Health Organization).

A long-standing philosophical divide in MgSO₄ practice concerns whether bedside clinical examination alone is sufficient for safety monitoring or whether routine serum magnesium levels should be mandated. Many obstetric programs, and several contemporary guidelines, explicitly favor a “clinical reflex–first” approach: deep-tendon reflexes, respiratory rate, and urine output are assessed at the bedside according to standardized observation charts, while serum magnesium levels are obtained only when renal function is impaired, infusions are prolonged, body habitus is extreme, or the examination is equivocal (National Institute for Health and Care Excellence NICE, 2019; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). Recent Australasian guidance recommends scheduled bedside observations and discourages routine levels unless renal dysfunction is present or toxicity is suspected, and the United Kingdom National Institute for Health and Care Excellence guideline NG133 (Hypertension in pregnancy) guideline similarly centers monitoring on clinical signs within hypertensive-disorder pathways (National Institute for Health and Care Excellence NICE, 2019; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). International consensus documents further urge each unit to maintain a uniform protocol for MgSO₄ use and monitoring, with clinical observation and outcome auditing as the cornerstone (Magee et al., 2022a). This stance is coherent with the exposure–toxicity sequence summarized in Section 4.4 and the “clinical-first, level-supported” strategy outlined in Sections 4.5 and 6.4.

In contrast, some institutions adopt a more “lab–first” philosophy, advocating scheduled serum magnesium measurements to “hit” a predefined therapeutic window and reduce interindividual variability in exposure. Proponents point to heterogeneous pharmacokinetics in pregnancy, obesity, diuretic use, and renal impairment, arguing that fixed-rate infusions can produce subtherapeutic or toxic concentrations in a minority of patients (National Institute for Health and Care Excellence NICE, 2019; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). From this perspective, routine levels are viewed as a way to standardize practice, address medico-legal concerns, and compensate for variable skill in reflex assessment. However, direct evidence that universal level monitoring improves maternal or neonatal outcomes over high-quality clinical surveillance is limited, and lab-based strategies may be constrained by turnaround times, resource use, and feasibility in low-resource settings.

Syntheses of current guidelines and consensus statements therefore lean toward a pragmatic compromise: clinical signs remain the primary real-time safety anchor for all patients, while serum magnesium levels are used selectively in higher-risk situations—impaired or deteriorating renal function, nonstandard or prolonged regimens, extremes of BMI, equivocal examinations, or co-therapies that plausibly alter magnesium handling (Magee et al., 2022a; National Institute for Health and Care Excellence NICE, 2019; Society of Obstetric Medicine of Austr alia and New Zealand SOMANZ, 2023). Within this hybrid model, units are encouraged to adopt a single, explicit monitoring protocol and to audit both processes (e.g., completeness of RR/DTR/UO documentation) and outcomes, rather than choose between reflex-only and lab-only extremes. The practical implementation of this compromise is detailed in Section 6.4, and consolidated action steps are summarized in Box 1 (Practice checklist).

A recurring question is whether one MgSO₄ regimen family should be regarded as the global “standard,” or whether multiple context-adapted regimens can be considered equivalent. Historically, the IM Pritchard regimen (IV loading followed by IM maintenance) has been favored where infusion pumps are scarce, whereas the IV Zuspan regimen (IV loading plus continuous 1–2 g/h infusion) is preferred in settings with pumps and continuous monitoring (National Institute for Health and Care Excellence NICE, 2019; Diaz et al., 2023). The 2023 Cochrane update comparing alternative regimens found broadly similar seizure outcomes across standard families (Pritchard, Zuspan, reduced-dose variants), with between-regimen differences driven more by feasibility and adverse-effect profiles than by clear efficacy separation; IM strategies carry injection-site pain and occasional abscess, whereas continuous IV regimens require reliable pumps and nursing vigilance (Diaz et al., 2023). These data support the view that multiple regimens can be acceptable, provided that recommended loading doses are delivered and basic monitoring is in place.

A related debate concerns how far dose and duration can be simplified. Low-dose variants such as the Dhaka regimen aim to reduce toxicity and resource demands, and several observational and trial data suggest that, in selected populations, lower maintenance doses and shorter postpartum courses (e.g., 12 vs. 24 h) do not clearly increase eclampsia risk (Diaz et al., 2023; Shaheen et al., 2024; Quist-Nelson et al., 2024; Begum et al., 2001). Critics note that most studies are underpowered for rare outcomes and conducted in specific settings, raising questions about generalizability; some guideline panels therefore remain cautious about endorsing aggressive dose reductions or very short durations as default care (Magee et al., 2022a; National Institute for Health and Care Excellence NICE, 2019). The balance between avoiding underexposure (breakthrough seizures) and minimizing cumulative dose and monitoring burden is particularly delicate in women with renal impairment or extreme BMI (Section 6.5).

From an implementation perspective, a pragmatic compromise is emerging. Rather than seeking a single universally superior regimen, many experts advocate that each institution or network (i) adopt one primary regimen family (Pritchard- or Zuspan-based) plus, where needed, a clearly defined alternative; (ii) ensure that loading doses are standardized and maintenance options (IV vs. IM, 12 vs. 24 h) are explicitly linked to local resources and patient risk; and (iii) monitor for breakthrough seizures, toxicity, and feasibility over time (Magee et al., 2022a; Diaz et al., 2023). Section 5.1.3 summarizes practical route and regimen choices in resource-constrained settings, while Box 1 distills key action points for regimen selection and program support.

Published evidence explicitly characterizing global diversity in antenatal MgSO₄ neuroprotection dosing and timing is limited; available professional guidance therefore suggests relatively low diversity in core practice, with most protocols converging on fixed loading-plus-maintenance regimens when preterm birth is imminent before approximately 30–32 weeks’ GA, while regional variation occurs mainly at the margins (e.g., gestational-age cutoffs and repeat-dose policies) (Crowther et al., 2023; Hywel Dda University Health Board, 2024). UK/Wales guidance operationalizes a practical window—ideally starting ∼4 h before birth but recommending administration even when the interval is shorter—reflecting real-world labor dynamics (Hywel Dda University Health Board, 2024). Notably, the MAGENTA randomized trial at 30–34 weeks evaluated a loading-dose–only (bolus-only) regimen (without a maintenance infusion) and reported no significant reduction in death or CP at 2 years; this hypothesis-generating finding raises the possibility that shorter bolus-only exposure may be insufficient for neuroprotection at later gestations, tempering enthusiasm for routine use beyond ∼30–32 weeks and reinforcing jurisdictional variability above that threshold (Crowther et al., 2023). Implementation programs such as Prevention of Cerebral Palsy in PreTerm Labour show that standardized prompts, checklists, and training can increase appropriate MgSO₄ use without major safety signals, although effects depend on local baseline performance and fidelity (Edwards et al., 2025).

In acute severe hypertension (≥160/110 mmHg) or high eclampsia risk, two time-critical tasks compete for attention: seizure prophylaxis or treatment with MgSO₄ and rapid BP control with fast-acting antihypertensives (e.g., IV labetalol, IV hydralazine, oral immediate-release nifedipine; IV nitroglycerin when pulmonary edema is present) (National Institute for Health and Care Excellence NICE, 2019; Countouris et al., 2025). Traditional teaching in some settings emphasized “magnesium first” to prioritize seizure prevention, whereas other teams focused on “BP first” to reduce intracerebral hemorrhage risk. Systems-oriented statements and recent expert reviews now converge on a two-track strategy, in which MgSO₄ and antihypertensives are initiated in close succession or in parallel whenever feasible, rather than sequentially in a way that delays either component (Edwards et al., 2025; National Institute for Health and Care Excellence NICE, 2019; Countouris et al., 2025).

The controversy is driven less by biology than by workflow and safety concerns. Advocates of a magnesium-first sequence note that eclampsia can occur before antihypertensive therapy takes effect and that MgSO₄ has limited impact on systemic BP at obstetric doses (Countouris et al., 2025; Magley et al., 2025). Others worry that starting MgSO₄ in a patient with uncontrolled severe hypertension and limited monitoring could blunt neurologic assessment or contribute to hypotension if antihypertensives are then rapidly escalated (Countouris et al., 2025). Direct comparative data on different sequencing strategies are sparse, and most reports bundle both interventions within broader emergency-response pathways, making it difficult to isolate the independent effect of order.

A pragmatic synthesis is to treat sequencing as a coordination problem rather than a rigid rule. The shared principle is that both therapies should be delivered rapidly, by clearly assigned team members, with continuous bedside monitoring of mental status, respiratory rate, DTRs, and BP (National Institute for Health and Care Excellence NICE, 2019). In practice, whichever intervention can be started safely first—for example, an oral nifedipine dose while IV access is established, or an MgSO₄ loading dose while antihypertensive orders are being prepared—should not be delayed, provided that the second arm follows promptly. Operational details, including time-bound BP targets and bundle design, are described in Sections 5.4 and 7.2–7.3; Section 11 reframes these combined actions as core maternal-safety priorities.

Beyond obstetrics, perioperative and ICU data suggest that IV MgSO₄ can reduce peri- and postoperative analgesic needs, opioid consumption, and postoperative nausea and vomiting, with occasional reports of delayed emergence—effects attributed to NMDA antagonism and calcium-channel actions (Yue et al., 2022). Randomized trials also report less emergence agitation and reduced intraoperative remifentanil use when MgSO₄ is co-administered, though effect sizes vary by procedure and background multimodal analgesia (Su et al., 2023). However, neutral observational findings exist (e.g., urologic cohorts without clear PACU pain benefit), underscoring context dependence (Salevitz et al., 2024). Clinically salient drug interactions include potentiation and prolongation of nondepolarizing neuromuscular blockers (notably rocuronium), mandating quantitative neuromuscular monitoring and appropriate reversal per American Society of Anesthesiologists 2023 guidance; additive sedation, bradycardia, and hypotension may emerge with propofol, dexmedetomidine, benzodiazepines, and opioids, requiring dose titration and vigilance (Thilen et al., 2023).

There is broad agreement that (i) MgSO₄ is first-line for eclampsia prophylaxis and treatment and for fetal neuroprotection when very preterm birth is imminent; (ii) bedside clinical monitoring is foundational; and (iii) regimen choice should fit resources while achieving therapeutic exposure without toxicity. Debate persists over universal lab monitoring vs. selective levels, specific regimen superiority (IM vs. IV vs. hybrid), upper GA boundaries and repeat neuroprotection courses, and the net perioperative/ICU benefit across procedures and co-sedatives.

Practically, programs should (a) embed a reflex-first monitoring protocol with triggers for serum levels (renal impairment, prolonged infusion, atypical exams); (b) select IV or IM maintenance to match equipment and staffing; (c) align neuroprotection with local GA policy and “give even if < 4 h” when delivery is imminent; (d) ensure antihypertensive treatment within 30–60 min alongside MgSO₄; and (e) in the OR/ICU, apply quantitative neuromuscular monitoring and hemodynamic vigilance when co-administering MgSO₄ with sedatives and analgesics.

Despite routine use, contemporary PK–PD data for MgSO₄ remain sparse in clinically complex obstetric populations—those with renal dysfunction, obesity/extreme BMI, multiple gestation, and ICU-level comorbidities (e.g., sepsis, cardiopulmonary disease). Recent population PK work in preeclampsia confirms substantial interindividual variability and identifies weight and disease severity as covariates, but many models lack CrCl or estimated glomerular filtration rate (eGFR), albumin, and explicit maternal–fetal compartments needed to inform exposure targets across settings (Deng et al., 2024). Future models should prospectively incorporate dynamic renal function, fluid shifts, and fetal transfer to link concentrations with both seizure suppression and toxicity end points. Standardized exposure–response outcomes—loss of deep-tendon reflexes, respiratory-rate thresholds, seizure recurrence—should be embedded alongside serum magnesium (total and, where feasible, ionized) to enable model-informed dosing. The latest preeclampsia PK study demonstrates the feasibility of such designs but underscores remaining covariate gaps and the need for simulation-tested regimens beyond “one-size-fits-all” programs (Deng et al., 2024). Renal-handling reviews further emphasize the predominance of renal clearance and the sharp rise in toxicity risk with reduced GFR, yet pregnancy-validated dose-adjustment algorithms are lacking (Adomako and Yu, 2024).

Modern, adequately powered randomized trials directly comparing Pritchard (IV load + IM maintenance), Zuspan (IV load + continuous infusion), and hybrid or bolus-dominant dosing—using standardized workflow and toxicity outcomes—are scarce. The updated Cochrane comparison of alternative regimens found no high-certainty evidence that any single approach is superior for major maternal or perinatal outcomes, reflecting small, heterogeneous studies and underscoring the need for pragmatic, multicountry head-to-head trials stratified by resource level and infusion-pump availability (Diaz et al., 2023).

Perioperative and ICU data suggest anesthetic- and analgesic-sparing effects with MgSO₄, but the magnitude of interactions with propofol, dexmedetomidine, midazolam, and opioids remains incompletely quantified for obstetric populations (onset, duration, dose–response, and hemodynamic trade-offs). High-quality randomized evidence confirms potentiation and prolongation of nondepolarizing neuromuscular block (e.g., rocuronium), yet recovery kinetics and reversal dosing are still insufficiently characterized for cesarean and postpartum ICU cohorts, arguing for obstetric-specific trials with quantitative neuromuscular monitoring and prespecified safety end points (bradycardia, hypotension, delayed emergence) (Benette et al., 2025).

The neuroprotective effect of antenatal MgSO₄ on CP is consistent, but longer-term neurodevelopment beyond 2 years is underreported, and benefits at later GA remain uncertain. The 2024 synthesis highlights reductions in CP and death/CP but calls for longer-term follow-up and better generalizability to LMIC settings (Shepherd et al., 2024). At 30–34 weeks’ gestation, the MAGENTA randomized trial showed no significant effect on death or CP at 2 years, underscoring the need to refine gestational-age windows and to power studies for clinically meaningful differences in contemporary care (Crowther et al., 2023). Notably, MAGENTA evaluated a loading-dose–only (bolus-only) regimen without a maintenance infusion; future studies should therefore explicitly test regimen design and exposure duration (e.g., bolus-only vs. longer-exposure strategies) to determine whether insufficient exposure contributes to the lack of observed benefit at later gestations (Crowther et al., 2023). Lactation safety summaries indicate very low infant exposure and generally reassuring clinical experience, but systematic pharmacovigilance beyond the early neonatal period is limited, and harmonized reporting of breastfeeding outcomes is needed [Drugs and Lactation Database (LactMed®), 2006)].

Digitized maternity early-warning scores (MEWS/MEOWS) are being developed nationally, yet external validation, calibration drift, and transportability across hospitals and subgroups (e.g., hypertensive disorders) remain major gaps. UK national score development work explicitly identified the need for prospective validation and impact evaluation before widespread adoption, including delineation of escalation pathways that integrate timely MgSO₄ initiation (Gerry et al., 2024). Future studies should report subgroup performance (preeclampsia/eclampsia, obesity, renal impairment), fairness metrics, and workflow impacts (false-alarm burden vs. time-to-treatment gains).

Health-system bundles (order sets, nursing checklists, EHR alerts) are widely promoted to accelerate treatment of severe hypertension and ensure timely MgSO₄ administration, but formal cost-effectiveness and budget-impact evaluations of these MgSO₄-inclusive bundles are rare. Available economic frameworks from broader hypertensive-disorder packages (e.g., Community-Level Interventions for Pre-eclampsia program analyses in LMICs) offer templates—choice of perspective, time horizon, and inclusion of maternal strokes prevented, SMM, neonatal ICU days, and readmissions—that should be adapted to facility-level MgSO₄ implementation, with equity-stratified reporting (Van Iseghem et al., 2025).

Across domains, consensus core outcome sets should be adopted: (1) exposure metrics (total and ionized magnesium, timing relative to delivery); (2) maternal clinical outcomes (eclampsia, recurrent seizures, reflex/respiratory toxicity, need for calcium rescue, ICU transfer); (3) neonatal outcomes (CP, severe intraventricular hemorrhage, ventilation days, NICU length of stay, breastfeeding continuity); and (4) implementation outcomes (time-to-treatment, adherence, alarm/alert acceptance). Studies should preregister analysis plans, publish model code and dosing simulators, and commit to multisite external validation.

An immediate opportunity is a model-informed precision dosing (MIPD) pathway that individualizes MgSO₄ to renal function, body size, and dynamic fluid shifts. Recent popPK work in preeclampsia demonstrates substantial interindividual variability and supports simulation-based dose optimization; future models should routinely include eGFR/CrCl, BMI, serum albumin, and time-varying fluid balance, with explicit maternal–fetal compartments to link exposure with seizure suppression and toxicity end points (Deng et al., 2024). Given the predominance of renal elimination and the rapid escalation of toxicity with reduced GFR, integrating kidney function into dosing logic is essential (Adomako and Yu, 2024). At the bedside, sparse sampling (for example, 1–2 serum magnesium levels during maintenance) can feed Bayesian updates to refine infusion rates in real time—an approach widely described for therapeutic drug monitoring–to–MIPD transitions in other domains and readily portable to MgSO₄ (Wicha et al., 2021). Clinically, this pathway should be embedded in the EHR: a standardized order set (loading and maintenance), a covariate capture panel (weight, eGFR, urine output), exposure targets (for example, a therapeutic band defined by seizure-prophylaxis vs. toxicity thresholds), and a decision-support widget that ingests a single level and proposes a revised rate with guardrails for renal impairment (Deng et al., 2024; Adomako and Yu, 2024; Wicha et al., 2021).

Conventional trials remain necessary but should adopt pragmatic designs that reflect real-world workflows. Stepped-wedge or cluster-randomized rollouts across L&D, ED, and postpartum units can test “dose-to-target” algorithms or regimen families (IV vs. IM vs. hybrid) using co-primary outcomes: (i) time-to-target BP (initiation within 30–60 min) and (ii) composite maternal–fetal outcomes (eclampsia or ICU transfer; neonatal severe morbidity), with equity stratification by race/ethnicity, language, and rurality (Countouris et al., 2025). Registry-embedded trials can leverage existing severe-hypertension pathways and early-warning systems to capture fidelity, escalation timing, and adverse events at scale (Countouris et al., 2025; Gerry et al., 2024). To complement neuroprotection evidence, new trials should oversample LMIC sites and specify longer-term child outcomes beyond 2 years, responding to calls from recent systematic reviews for durable neurodevelopmental follow-up and broader generalizability (Shepherd et al., 2024).

Digitized maternity early-warning scores (MEWS/MEOWS) provide a validated foundation for algorithmic surveillance and escalation (Gerry et al., 2024). Next-generation systems should fuse continuous vital-sign streams (respiratory rate, oxygen saturation), urine output, and neuromuscular monitoring (when nondepolarizing blockers are co-administered) to detect impending MgSO₄ toxicity—e.g., rising apnea risk or loss of reflexes—while simultaneously prompting antihypertensive action when severe BP is sustained (Countouris et al., 2025; Gerry et al., 2024). After discharge, remote postpartum BP programs can extend this safety net, enabling algorithm-driven triage and rapid treatment of late-worsening hypertension; such programs have demonstrated feasibility and improved capture of at-risk patients in safety-net populations (Mujic et al., 2024). Any AI or alert feature must undergo prospective validation, include drift monitoring, and maintain human-in-the-loop oversight to avoid automation bias and alert fatigue (Countouris et al., 2025; Gerry et al., 2024; Mujic et al., 2024).

Future practice should codify shared governance across obstetrics, anesthesia, ICU, and neonatology for MgSO₄ co-administration. Standard operating procedures need to define handoffs (admission → delivery → PACU/ICU → postpartum), neuromuscular monitoring rules when MgSO₄ is combined with rocuronium or other nondepolarizing agents, and reversal workflows consistent with 2023 American Society of Anesthesiologists guidance (quantitative monitoring and timely antagonism) (Thilen et al., 2023). Service-level agreements should specify escalation timelines (e.g., treatment within 30–60 min), documentation requirements, and a cross-service debrief process after any seizure, toxicity rescue, or ICU transfer (Thilen et al., 2023; Countouris et al., 2025).

Scale-up will depend on a “minimum viable bundle” that functions with or without infusion pumps: a single standardized order set (with IV and IM branches), a bedside checklist (reflexes, respirations, urine output), an escalation pathway for severe BP, and a simple data form for timeliness and outcomes. This starter bundle can begin on paper and transition to the EHR as capacity grows, following the national-to-facility architecture promoted by the WHO QCN (coaching, micro-audits, and iterative learning) (World Health Organization). Cost-effectiveness should be embedded in implementation studies; extended evaluations of national programs integrating antenatal MgSO₄ have shown that effectiveness and cost-effectiveness can be appraised together, informing procurement and workforce planning for sustained adoption (Edwards et al., 2025). Where remote monitoring is feasible, postpartum BP programs should be bundled with MgSO₄ pathways and audited for equity—ensuring that gains are shared across language and rurality strata (Countouris et al., 2025; Mujic et al., 2024).

Data → Model → Bedside tool → Trial → Scale-up: collect covariates (eGFR, BMI, fluid balance) and sparse levels → develop popPK models with Bayesian updating and exposure targets → build EHR decision support that proposes maintenance rate adjustments → conduct cluster or registry trials measuring timeliness and maternal–fetal outcomes with equity analyses → scale nationally via QI collaboratives and WHO QCN, with embedded cost-effectiveness (Edwards et al., 2025; Deng et al., 2024; Adomako and Yu, 2024; Countouris et al., 2025; Gerry et al., 2024; World Health Organization; Wicha et al., 2021).

Adults with preeclampsia/eclampsia in hospital clusters (mixed acuity) would be randomized by stepped-wedge design to MIPD-guided versus standard MgSO₄. Primary endpoints: initiation within 30–60 min and an eclampsia/ICU-transfer composite by 48 h. Secondary endpoints: toxicity rescue events, neonatal severe morbidity, and length of stay, with 6–24-month neurodevelopmental follow-up in a predefined subgroup. Equity analyses would use interaction terms for race/ethnicity, language, and rurality (Shepherd et al., 2024; Countouris et al., 2025).

Clinical and institutional leaders should approach MgSO₄ as part of an integrated maternal-safety bundle rather than an isolated drug protocol. Priority actions are to: recognize acute severe hypertension rapidly; initiate treatment within 30–60 min; and start MgSO₄ in parallel when indicated. Bedside monitoring should consistently use the triad of respiratory rate, deep-tendon reflexes, and urine output, with explicit thresholds for holding or adjusting therapy. Order sets and handoff checklists should incorporate context-aware dosing and duration that reflect renal function, body size, gestational age, and care setting. For threatened early preterm birth, antenatal MgSO₄ should be operationalized as a routine neuroprotection step once birth is likely, without delaying indicated delivery. Box 1 summarizes practice-ready checklists for acute hypertension, seizure prophylaxis, fetal neuroprotection, and perioperative/ICU guardrails.

Durable reliability requires aligned tools, teams, and digital infrastructure. Standardized electronic order sets, well-designed alerts, and structured handoffs should be coupled with simulation-based team training, pharmacy support, and bedside nursing protocols so that MgSO₄ bundles are delivered consistently across L&D, emergency, and ICU environments. Where electronic alerts are used, they should be validated for calibration and false-alarm burden, assigned clear clinical ownership, and monitored for drift over time, with explicit escalation rules and rollback plans. Example 90-day playbooks, operational cadence, and candidate KPI targets are provided in Supplementary Box S1 and can be adapted to local governance structures and resource constraints.

Measurement and equity need to be built in from the outset. Programs should track timeliness of treatment for acute severe hypertension, completion of MgSO₄ regimens, monitoring completeness, antenatal neuroprotection uptake, and postpartum blood-pressure follow-up, using run charts and regular case review to identify gaps. Many quality-improvement collaboratives set pragmatic targets—for example, achieving timely treatment in at least 80%–90% of eligible cases within a few quarters—while using equity-stratified dashboards to ensure that progress is shared across language, insurance, and geographic subgroups. Table 2 presents a compact KPI panel that can be tailored to local priorities. At regional and national levels, aligning MgSO₄ bundles with WHO QCN tools, publishing open templates for order sets and checklists, and incorporating budget-impact and cost-effectiveness analyses can support scale-up and sustained investment, particularly in resource-constrained settings.